



Press Release

----- 12/1/2006:

Charisela Technologies , Inc. Is proud to announce the release of its first reagent kit -Quantifier Insulin Assay- The first in a series of reagents off the Quantifier Reagent Line.

San Jose, Calif.---Charisela Technologies, Inc. today announced the release of its newest reagent kit: Quantifier Insulin Assay. Based on its proprietary, patent pending and novel methodologies providing low background, rapid, non-radioactive and accurate results, the Quantifier Insulin Assay has the potential of becoming the choice reagent for high content insulin screening.

Insulin is the primary hormone responsible for conversion of glucose to glycogen. Insulin is a polypeptide hormone with a molecular weight 5800. Insulin is secreted by special cells (Langerhans Cells) in the pancreas. Several physiological effects of insulin also serve to lower blood and tissue glucose levels. Inadequate secretion of insulin by the Islets of Langerhans result in elevated blood glucose levels leading to (Type I Diabetes). Normal or elevated concentrations of insulin can be found in patients with Type II Diabetes, where resistance or insensitivity to insulin cause an increase in glucose levels. Advances in biotechnology has demonstrated great progress in recombinant insulin production as well as in culturing and harvesting of insulin producing cells. Charisela's Insulin assay is geared specifically for these institutions that yield high concentration insulin secretion via harvesting of these cells either for recombinant manufacturing or transplantation purposes.

Charisela Technologies is focused on developing novel, custom and OEM consumables in forms of reagents and cell based assays that provide: Ease of use, cost efficacy, rapid and reliable products with regards to diabetes research, infectious diseases, drug discovery and cellular analysis for the biotech and pharmaceutical industries. Technologies used by Charisela will allow the company to incorporate a flexible assay design in terms of ease of use and custom products for customers specific needs. Charisela prides itself on rapid and reliable assay development that allows its customers to expedite drug screening research, diabetes, cancer, and infectious diseases research. Charisela also provides a symbiosis with instrument manufacturers by opening their markets to instrument sales on reagents developed for those instruments by Charisela via partnership, collaboration or custom requests.

Charisela Technologies
5941 Optical Ct. Suite 205
San Jose, CA 95138
Tel: 408-960-2936